- Home
- ELOX
as of 10-01-2026 11:22am EST
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.
| Founded: | 1999 | Country: | United States |
| Employees: | N/A | City: | ARLINGTON |
| Market Cap: | 60.3M | IPO Year: | 2013 |
| Target Price: | $38.25 | AVG Volume (30 days): | 21.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.48 | EPS Growth: | 41.67 |
| 52 Week Low/High: | $10.00 - $23.40 | Next Earning Date: | 08-12-2026 |
| Revenue: | N/A | Revenue Growth: | -100.00% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -10.09 | Index: | N/A |
| Free Cash Flow: | -6393000.0 | FCF Growth: | N/A |
Earnings Transcripts
SEC 8-K filings with transcript text
2026 Q2 Q2 2026 Earnings
8-K Aug 11, 2026
Q2 2026 Earnings
8-KAug 11, 2026
2023 Q3 Q3 2023 Earnings
8-K Nov 13, 2023
Q3 2023 Earnings
8-KNov 13, 2023
2023 Q1 Q1 2023 Earnings
8-K May 16, 2023
Q1 2023 Earnings
8-KMay 16, 2023
Compare ELOX vs Leading Stocks
See how ELOX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ELOX Eloxx Pharmaceuticals Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.